[Federal Register Volume 88, Number 104 (Wednesday, May 31, 2023)]
[Notices]
[Pages 34857-34858]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-11498]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality


Notice of Meeting

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) 
announces a Special Emphasis Panel (SEP) meeting on ``Supporting the 
Management of Substance Use Disorders in Primary Care and other 
Ambulatory Settings (R18)''. This SEP meeting will be closed to the 
public.

DATES: July 13, 2023.

ADDRESSES: Agency for Healthcare Research and Quality (Video Assisted 
Review), 5600 Fishers Lane, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT: Jenny Griffith, Committee Management 
Officer, Office of Extramural Research, Education and Priority 
Populations, Agency for Healthcare Research and Quality, (AHRQ), 5600 
Fishers Lane, Rockville, Maryland 20857, Telephone: (301) 427-1557.

SUPPLEMENTARY INFORMATION: A Special Emphasis Panel is a group of 
experts in fields related to health care research who are invited by 
AHRQ, and agree to be available, to conduct on an as needed basis, 
scientific reviews of applications for AHRQ support. Individual members 
of the Panel do not attend regularly scheduled meetings and do not 
serve for fixed terms or a long period of time. Rather, they are asked 
to participate in particular review meetings which require their type 
of expertise.
    The SEP meeting referenced above will be closed to the public in 
accordance with the provisions set forth in 5 U.S.C. 1009(d), 5 U.S.C. 
552b(c)(4), and 5 U.S.C. 552b(c)(6). Grant applications for 
``Supporting the Management of Substance Use Disorders in Primary Care 
and other Ambulatory Settings (R18)'' are to be reviewed and discussed 
at this meeting. The grant applications and the discussions could 
disclose confidential trade secrets or

[[Page 34858]]

commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.
    Agenda items for this meeting are subject to change as priorities 
dictate.

    Dated: May 24, 2023.
Marquita Cullom,
Associate Director.
[FR Doc. 2023-11498 Filed 5-30-23; 8:45 am]
BILLING CODE 4160-90-P